Victoria Johnson

Sana Somani, MD, MBBS, vascular neurology fellow at the University of Maryland Medical Center, discussed her research into disparities in post-stroke care.

A recent paper supported by several presentations at AAN 2021 elucidate areas of migraine care to improve.

Marian LaMonte, MD, MSN, FAAN, chief of neurology at Ascension Saint Agnes, discussed her team’s efforts to improve compliance in providing stroke discharge instructions.

A budget impact analysis suggested that Cala Health’s Cala Trio device can serve as a cost-saving treatment option for patients with ET.

Jason Poon, MD, neurologist at University of Utah, discussed his study on diagnostic accuracy in telestroke consultations.

The trial design was presented at the 2021 ENCALS meeting and is set to run for 48 weeks at more than 50 clinical centers.

The investigational drug, previously granted fast-track designation, did not meet primary or secondary end points in the ORARIALAS-01 trial.

The study will be based in West Haven, Connecticut, and enroll up to 100 veterans with the headache disorder.

Robert Fox, MD, Vice-Chair for Research at the Cleveland Clinic Neurological Institute, discussed the findings of the phase 2 EMPhASIS trial of this investigational MS therapy.

The 2 organizations will use whole-genome sequencing and clinical characterization to investigate the genetic causes of CP.

Data presented at the ASGCT 2021 meeting showed increased microdystrophin expression with SGT-001.

Northwell Health will conduct a NIH-funded study assessing the effects of the experimental drug in treating patients with ICH.

William Noah, MD, director and founder of the Sleep Centers of Middle Tennessee, discussed the aim of his practice’s study.

In addition to comorbidity frequency, the researchers also studied the comparison of comorbidities between men and women with migraine.

Clive Ballard, MD, the executive dean at the University of Exeter Medical School, discussed the safety and efficacy profile of pimavanserin (Nuplazid; Acadia Pharmaceuticals).

The partnership combines Capsigen’s vector engineering with Biogen’s drug pipeline, seeking to develop gene therapies for neuromuscular and central nervous system disorders.

Kathy Zackowski, PhD, OTR, senior director of patient management, care, and rehabilitation research at the National MS Society discussed her team’s call to action for research.

A recent study showed improvements in animals with mutant huntingtin protein treated with AFFiRiS AG’s investigational monoclonal antibody.

Daniel Reich, MD, PhD, senior investigator at the National Institutes of Neurological Disorders and Stroke, spoke about his investigations into the role of microglia in progressive MS.

A recent study identified 3 novel loci that are associated with Parkinson disease progression to dementia: RIMS2, TMEM108, and WWOX.

Spencer Hutto, MD, a fellow of autoimmune neurology at Massachusetts General Hospital, discussed his team’s investigation into demyelinating events after the use of TNFαi inhibitors.

A recent review outlined the clinical features, pathophysiology, and treatments for cluster headache, finding noninvasive vagus nerve stimulation to be effective in various ways.

Recent Foundation for Angelman Syndrome Therapeutics grants funded the hotline as well as work to develop cell line models for rarer genotypes of AS.

Researchers found that patients with epilepsy that later died from SUDEP had an abnormal cardiac response after hyperventilation.

A survey of more than 500 individuals also found that dyskinesia impacted social interactions and reported that OFF time was isolating.

The World Sleep Society Narcolepsy Task Force surveyed clinicians in an effort to understand regional differences in the diagnosis and management of narcolepsy.

Investigators also studied how use of a patient engagement tool influenced adherence rates to PAP.

Researchers compared sleep measures between the Fitbit Charge 3, the Actigraph GT9X accelerometer, and polysomnography.

Researchers also found that EDSS score pre-pregnancy was associated with the likelihood of post-partum relapse for patients with multiple sclerosis.

William Noah, MD, director and founder of the Sleep Centers of Middle Tennessee, discussed findings from his study on PAP adherence.